Huang CY, et al. - The goal of this analysis was to examine the levels of vascular endothelial growth factor (VEGF) in the systemic circulation of patients with type 1 retinopathy of prematurity (ROP), who received intravitreal injections of 1 mg (0.025 mL) aflibercept (IVA) or 0.625 mg (0.025 mL) bevacizumab (IVB). Findings displayed a suppression of the serum VEGF levels and the VEGF/PLT ratio in such individuals for 3 months after treatment with either IVA or IVB. However, pronounced suppression of systemic VEGF was noted among patients treated with IVB than those treated with IVA.